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Abstract
Purpose Evaluation of three aflibercept injections at 4-week
intervals in patients with neovascular AMD showing an “in-
sufficient anatomic response” to prior anti-VEGF therapywith
ranibizumab or bevacizumab.
Methods The retrospective analysis included 96 eyes that had
received at least three intravitreal 0.5 mg ranibizumab or
1.25 mg bevacizumab injections over a period of no more
than 4 months prior to switching to aflibercept. In addition, the
selected eyes had to have evidence of persisting or increasing
sub- or intraretinal fluid, observed in optical coherence to-
mography (OCT). All patients received a loading dose of three
intravitreal 2 mg aflibercept injections at 4-week intervals.
Evaluation included central retinal thickness (CRT) and max-
imum pigment epithelium (PED) height measured by spectral
domain OCTand best-corrected visual acuity (BCVA) prior to
the switch of therapy and 4 weeks after the third aflibercept
injection.
Results A significant reduction of mean CRT (−39 μm;
p<0.001) and maximum PED height (−46 μm; p<0.001) as
found 4 weeks after the third aflibercept injection. Eighty-two
out of 96 eyes (85 %) had a PED just prior to switching to
aflibercept. There was an improvement in BCVA of 1.9 letters
4 weeks after the last aflibercept injection; the vision gain,
however, did not reach statistical significance (p=0.061). The
further analysis did not show any correlation of the change in
CRT, maximum PED, and BCVA with the number of prior
anti-VEGF treatments.
Conclusion Retinal edema and PEDs regressed significantly
after switching to aflibercept in patients insufficiently
responding to prior therapy with ranibizumab or
bevacizumab. No correlation could be found with regard to
the number of prior treatments.
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Introduction
The introduction of intravitreal pan anti-vascular endothelial
growth factor (VEGF) blockade for neovascular age-related
macular degeneration (AMD) in the last decade has had a
significant beneficial impact on patients with neovascular
AMD [1–3]. However, information on long-term functional
outcomes on anti-VEGF therapy in neovascular AMD are
sparse and limited by decreasing number of patients in
follow-up. A 7-year follow-up study on ranibizumab indicates
a mean vision loss of more than 8 letters and 34 % of patients
having a loss of at least 3 lines in vision at the final visit [4].
The vision loss in long-term follow-up is probably multifac-
torial. It includes natural progression of the underlying non-
neovascular AMD, too few anti-VEGF treatments despite a
still active disease, and the loss of treatment effectiveness over
time [5].
Several studies have shown that a reduced anatomic re-
sponse can be found for ranibizumab and bevacizumab in
neovascular AMD over time [6, 7]. The terms used for this
finding, range from tolerance or tachyphylaxis to resistance
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[5]. It is assumed that persistent intra- or subretinal edema
will lead to degenerative changes and subsequent vision
loss. Various reasons, including up-regulation of alternative
pathways, autoantibodies, and impairment of the retinal
pigment epithelium (RPE) have been implicated [8]. To
overcome the “insufficient response”, several treatment strat-
egies have been used. Ranibizumab and bevacizumab have
been tried in exchange, showing some anatomic response in
most cases, but the functional success has been limited [9].
Short-term follow-up, in cases of reduced anatomic response
(at least some regression showed) could indicate that more
frequent retreatments might be useful to reduce edema.
However, retreatments that are more frequent than every
4 weeks have significant implications for patients, including
higher ocular risks and an additional financial burden as
such retreatments are often not reimbursed by health care
systems. Increasing the injected drug dose (mostly doubling)
appears as an alternative, but extends biological activity by
only one half-life time [10]. Moreover, the injection of
0.1 ml leads to a higher intraocular pressure (IOP) post-
injection than the usually used 0.05 ml. So far, there is
limited data on combination therapies with steroids or
photodynamic therapy [7].
Aflibercept is a new VEGF inhibitor that differs from
ranibizumab and bevacizumab by a higher affinity to
VEGF. By entrapping the VEGF dimer, aflibercept
avoids two drug molecules binding to one VEGF dimer.
In addition, aflibercept blocks the placental growth fac-
tor (PlGF). The presented study aimed to evaluate eyes
anatomically “insufficiently responding” to prior anti-
VEGF therapy with ranibizumab and bevacizumab in a
European population, with special focus on the prior
treatment history.
Methods
The presented study is a retrospective analysis of patients
treated with aflibercept for neovascular AMD at the depart-
ment of Ophthalmology at the City Hospital Triemli in Zurich.
The study adhered to the Declaration of Helsinki, and obtain-
ed exemption from full review by the local ethics committee.
Records of patients treated for neovascular AMD with a first
intravitreal aflibercept between November 2012 to May 2013
were reviewed based on defined inclusion criteria. To select
patients insufficiently responding to prior therapy, a two-step
selection process was used. The first criterion required that the
affected eye had received at least three intravitreal 0.5 mg
ranibizumab or 1.25 mg bevacizumab injections over a period
of no more than 4 months prior to switching to aflibercept.
Secondly, the selected eyes had to have evidence of insuffi-
cient anatomic response to prior therapy, defined as any
persisting or increasing sub- or intraretinal fluid observed in
spectral-domain optical coherence tomography (OCT) using
the Heidelberg Spectralis® system (Heidelberg Engineering,
Heidelberg Germany). All 19 standard scans (setting: 512 A
scans, 20° × 15°) were compared between scans taken just
prior to the first of the last three injections with ranibizumab or
bevacizumab therapy and the scans taken just prior to initia-
tion of aflibercept therapy. Evidence of any persisting sub- or
intraretinal fluid in any of the 19 scans was considered an
insufficient response. OCT scans were compared based on
“follow-up” mode of the eye-tracking-assisted Heidelberg
Spectralis® system (AutoRescan), allowing precise compari-
son. In general, all eyes initiated with aflibercept were planned
to receive three intravitreal 2 mg aflibercept injections at 4-
week intervals, with a final visit 4 weeks (±1 week) after the
last injection, according to the Swiss label of aflibercept. The
retrospective analysis included only eyes that effectively ob-
tained this treatment.
We recorded demographic data, the total number of intra-
vitreal pretreatments with ranibizumab and/or bevacizumab,
the time since initiation of any anti-VEGF therapy, the anti-
VEGF drug used prior to changing to aflibercept, the interval
between the last intravitreal pretreatment with ranibizumab or
bevacizumab, and the first aflibercept injection.
The primary outcome was the change in central retinal
thickness (CRT) measured by OCT 4 weeks after the third
aflibercept injection, compared to the time of change in
therapy.
Secondary outcome measures were the change in maxi-
mum height of a pigment epithelial detachment (PED) — if
present— as well as the change in best-corrected visual acuity
(BCVA) using Snellen visual acuity. The change in maximum
height of the PED was measured via the software’s ruler tool
in μm on the OCT image. For visual acuity analysis, Snellen
readings were transferred to ETDRS letters according to the
publication by Gregori et al. [11]. All measurements were
conducted just prior to the first aflibercept injection and
4 weeks (±1 week) after the third aflibercept injection.
Furthermore, we analysed whether the changes in CRT,
PED, or BCVA correlated with the total number of pretreat-
ments (i.e. using ranibizumab and/or bevacizumab), or with
the anti-VEGF drug used immediately prior to the change in
therapy. Finally, the intraocular pressure (IOP) immediately
prior to the change in therapy was compared to the IOP at the
final visit. Adverse events were recorded.
All statistical analyses were done using SPSS® Version 20.
For inferential statistics, non-parametric tests were performed
for all analyses, since distributions were not normal.
Differences were calculated by subtracting pretreatment data
from posttreatment data. Dependent samples were tested with
the exact Wilcoxon signed rank test, and independent samples
with the exact Mann–Whitney U test. Spearman’s rho was
calculated for all correlation analyses. Statistical significance
was defined as p<0.05.
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Results
A total of 109 eyes with neovascular AMD and pretreatment
with ranibizumab and/or bevacizumab fulfilled the definition
of an insufficient treatment effect, and were switched to ther-
apy with aflibercept. Thirteen eyes were not included in the
analysis because they had not received the three planned
injections, or because they did not fulfill the timing schedule.
Thus, a total of 96 eyes of 88 patients were analyzed.
The mean age of the involved patients was 78.9 years. Fifty-
three of the 96 treated eyes were of female patients. Themajority
of eyes were treated only with ranibizumab (n=64), four were
treated only with bevacizumab, and 28 eyes have been switched
from bevacizumab to ranibizumab or vice versa.
On average, a total of 26.9 anti-VEGF pretreatments with
ranibizumab and/or bevacizumab were administered prior to
changing therapy to aflibercept. Of these pretreatments, the
mean number of injections was 24.8 for ranibizumab and 9.2
for bevacizumab.
The first anti-VEGF treatment was given on average
35months prior to switch of therapy, and the mean retreatment
interval since initiation of any anti-VEGF therapy was
1.3 months.
The mean retinal thickness was 337 μm (median 322 μm)
before treatment with aflibercept compared to 298 μm follow-
ing three aflibercept injections (median 277 μm). Thus, with
regard to the primary outcome, we measured a significant
mean reduction in retinal thickness of 39 μm (p<0.001)
observed 4 weeks after the third aflibercept injection.
Patients with ranibizumab or bevacizumab as last pretreatment
preceding aflibercept injection did not differ significantly with
regard to retinal thickness before and after treatment (p=
0.739). No correlation between the total number of pretreat-
ments (i.e. ranibizumab and/or bevacizumab) and the change
in retinal thickness could be found (Spearman’s rho=0.069,
p =0.507). Figure 1a shows the point by point findings with
regard to change in CRT and number of pretreatments.
There were 83 eyes with a PED at the first assessment, of
which 82 eyes had valid data for PED at the follow-up visit.
Thus, 82 eyes were analyzed for PED.
The maximum height of PED decreased significantly by
46 μm (p<0.001) from a mean of 241 μm (median 208 μm)
prior to aflibercept injection to 195 μm (median 162 μm)
following the third aflibercept injection. The type of most
recent pretreatment (ranibizumab or bevacizumab) immedi-
ately prior to changing therapy did not have a significant
influence on maximum PED (p=0.910). No correlation be-
tween the total number of pretreatments (i.e. ranibizumab
and/or bevacizumab) and the change in maximum height of
the PED could be observed (Spearman’s rho=0.121, p =
0.278) as shown in the point by point presentation of “number
of prior treatments” and “change in maximum PED height” in
Fig. 1b.
MeanBCVAwas 61.6 letters prior to switching to aflibercept.
Four weeks after the third aflibercept treatment, there was an
increase of 1.9 letters in visual acuity, which was just below
significance level (p=0.061). The type of the most recent pre-
treatment (ranibizumab or bevacizumab) did not have a signif-
icant influence on the change in BCVA (p=0.986).
Similarly to CRTandmaximum PED height, no correlation
could be observed between the total number of pretreatments
and the change in BCVA (Sperman’s rho −0.107, p=0.298).
Figure 1c shows each BCVA outcome in association with the
number of pretreatments. Four eyes had a BCVA loss of more
than three lines. All four eyes showed an anatomic response
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Fig. 1 a Change in central retinal thickness 4 weeks after the third
treatment with aflibercept does not correlate with the total number of
prior anti-VEGF treatments with ranibizumab or bevacizumab
(Spearman’s rho 0.069, p=0.507). b Change in maximum PED height
4 weeks after the third treatment with aflibercept does not correlate with
the total number of prior anti-VEGF treatments with ranibizumab or
bevacizumab (Spearman’s rho 0.121, p=0.278). c Change in BCVA
4 weeks after the third treatment with aflibercept does not correlate with
the total number of prior anti-VEGF treatments with ranibizumab or
bevacizumab (Spearman’s rho −0.107, p=0.298)
Graefes Arch Clin Exp Ophthalmol (2014) 252:1705–1709 1707
(regression of intra- and subretinal fluid). In one eye, the
vision loss was transient, most likely due to a viral conjunc-
tivitis. In the other three eyes, vision loss was persistent and
attributed to atrophy of the RPE and/or fibrotic changes.
Figure 2 shows the central OCT scans of two of the eyes with
persistent vision loss of more than 3 lines.
No severe ocular or systemic adverse events occurred
within the 3-month follow-up period. Despite a high percent-
age of eyes with PEDs, no new tear of the RPE was seen
within the 3-month follow-up period. None of the eyes
showed a non-spontaneously resolving intraocular
inflammation under treatment with aflibercept. The mean
intraocular pressure showed a mild, but significant decrease
from 15.1 mmHg prior to aflibercept to 13.7 mmHg after the
third aflibercept injection (p<0.001).
Discussion
Switching anti-VEGF therapy to aflibercept in patients with
neovascular AMD who were showing insufficient anatomic
response with ranibizumab or bevacizumab was accompanied
by a reduction of central retinal thickness and maximum PED
height, in a short-term follow-up. An improvement in vi-
sual acuity by 1.8 letters did not reach statistical signifi-
cance. Our data are in line with other studies evaluating
aflibercept in cases of neovascular AMD showing insuffi-
cient anatomic response to previous anti-VEGF therapy
[12–17]. There is consistency with regard to an anatomical
improvement. However, not all studies show a significant
gain in visual acuity. Since visual acuity was not the
primary outcome of our study, intra- or subretinal fluid in
a subfoveal location was not an inclusion criterion, which
may explain the non-significant improvement in visual
acuity in our study. Other factors potentially providing
different functional results might include different lesion
types, variations in the definition of “insufficient response”
to previous therapy, and the type of treatment regimen used
with aflibercept.
Most studies with limited or no vision gain explain their
results with the long-standing disease. However, the present
study evaluated this aspect, but could not find a correlation of
increased anatomical or functional outcome with regard to
fewer pretreatments, as shown in Fig. 1a-c. This would indi-
cate that at least with regard to anatomical outcomes, a switch
in therapy would make sense. This is independent of the
number of pretreatments, if “insufficient anatomic response”
(as defined in our analysis) is seen with other anti-VEGF
agents. Reduced or absent edema could prevent vision loss
in further follow-up, which remains to be proven in studies
with long-term follow-up. The characteristics of the selected
patient population prior to starting aflibercept are worth men-
tioning. Visual acuity was relatively good with 61.6 letters
(20/63+) prior to switching to aflibercept, despite a mean of
26.9 prior anti-VEGF injections. These were performed on
average every 1.3 months. This patient population had initial-
ly lost 3.1 letters over a mean of 35.0 months with
ranibizumab and/or bevacizumab. This indicates that despite
no under-treatment (>9 injections per year on average), the
selected patient population did not perform well under
ranibizumab and bevacizumab. It also could imply that some
persistent fluid impairs functional outcomes.
Formerly, PEDs without significant growth were not con-
sidered as an indication for treatment in the case of absence of
intra- or subretinal fluid in neovascular AMD under prior anti-
VEGF treatment. The significant effect on PEDs after the
switch to aflibercept is remarkable, especially when taking
into consideration that many PEDs did not respond to previ-
ous therapy [16]. The questions therefore arise, whether we
should treat PEDs more aggressively with the new anti-VEGF
treatment option, and whether VEGF inhibition is related to
this effect. Despite a clear regression of PEDs under
aflibercept treatment, no new tear of the RPE occurred in
our study. Since an effect on PEDs was seen, the high number
Fig. 2 Spectral-domain optical coherence tomography images through the
foveal region prior to (a/c) and after (b/d) three aflibercept injections in two
cases with persistent edema with prior ranibizumab therapy. Despite the
resolution of intraretinal/subretinal fluid and a slight regression of the PED,
the two eyes lost more than 3 lines in vision. Both eyes had some degree of
pre-existing subfoveal RPE changes (arrows in a/c). Post aflibercept
treatment, RPE atrophy appears more evident (arrows in b/d). However
progression of preexisting atrophy cannot be concluded due to a potential
“masquerading” effect of edema present prior to switch of treatment
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of pretreatments might only be a partial explanation for the
absence of new RPE tears in this population.
It is unclear why all studies find reduced edema following a
switch to aflibercept. Theoretically, all VEGF should be
bound by intensive anti-VEGF therapy. Better retinal penetra-
tion appears rather unlikely, especially when compared to the
much smaller ranibizumab molecule. The additional binding
of the placental growth factor (PlGF) by aflibercept, its higher
binding affinity to VEGF compared to other VEGF inhibitors,
or the development of auto-antibodies to prior anti-VEGF
therapy, could serve as potential explanations [8].
In conclusion, the switch to aflibercept in neovascular
AMD “insufficiently responding” to prior anti-VEGF therapy
clearly has a beneficial anatomical effect, even on long-
persisting PEDs, and is worth a try independent of the number
of pretreatments.
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